Figure 3

Tumor response according to baseline levels of serum (A) CRP and NLR and changes in (B) CRP and (C) NLR levels after therapy. Tumor response was better in the group with both baseline serum CRP ≤ 6.3 mg/L and NLR ≤ 2.3 than the other groups (p < 0.001; Figure 3A). At follow-up, patients with progressive disease showed an increase in levels of CRP and NLR, whereas responders exhibited a decrease in the levels (repeated measures ANOVA, all p < 0.001; Figure 3B and 3C). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.